Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

3922 - Development of the Functional Assessment of Cancer Therapy-Immune Checkpoint Modulator (FACT-ICM): A scale to measure quality of life in cancer patients treated with ICMs

Date

30 Sep 2019

Session

Poster Display session 3

Topics

Immunotherapy

Tumour Site

Presenters

Aaron Hansen

Citation

Annals of Oncology (2019) 30 (suppl_5): v475-v532. 10.1093/annonc/mdz253

Authors

A.R. Hansen1, K. Ala-leppilampi2, C. McKillop3, L.L. Siu4, P. Bedard5, A.R. Abdul Razak5, A. Spreafico6, S. Sridhar7, N.B. Leighl8, M.O. Butler9, D. Hogg1, A. Sacher1, A.M. Oza1, R. Nisenbaum10, K.A. Webster11, D. Cella12, J. Parsons2

Author affiliations

  • 1 Division Of Medical Oncology, Princess Margaret Cancer Center, M5G 1Z6 - TORONTO/CA
  • 2 Applied Health Research Centre, Li Ka Shing Knowledg Institute, St. Michael's Hospital University of Toronto, Toronto/CA
  • 3 Medicine, Turalt Inc, M5B 2L7 - Toronto/CA
  • 4 Medical Oncology And Hematology Department, Princess Margaret Cancer Centre, M5G 1Z5 - Toronto/CA
  • 5 Medicine, Princess Margaret Cancer Center, M5G 1Z6 - Toronto/CA
  • 6 Medical Oncology And Hematology, Princess Margaret Cancer Center, M5G 1Z6 - Toronto/CA
  • 7 Medical Oncology, Princess Margaret Hospital, M5G 1Z6 - Toronto/CA
  • 8 Division Of Medical Oncology, Princess Margaret Cancer Centre, M5G 1Z6 - Toronto/CA
  • 9 Division Of Medical Oncology And Hematology, Princess Margaret Hospital, M5G 2M9 - Toronto/CA
  • 10 Applied Health Research Centre, Li Ka Shing Knowledg Institute, St. Michael's Hospital University of Toronto, M5B 1T8 - Toronto/CA
  • 11 Feinberg School Of Medicine, Northwestern University, 60611 - Chicago/US
  • 12 Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago/US

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3922

Background

Currently cancer patients treated with immune checkpoint modulators (ICMs) have their health related quality of life (HRQOL) measured by general patient reported outcome (PRO) tools such as the EORTC QLQC30 or Functional Assessment of Cancer Therapy-General (FACT-G). No instrument has been developed specifically for patients treated with ICMs, which may lead to their HRQOL being evaluated inaccurately. The objective of this study was to develop a toxicity subscale PRO instrument for ICM treated patients that would contribute to the measurement of HRQOL.

Methods

Input was collected from a prior systematic review, patients and physicians. Descriptive thematic analysis was used to evaluate the qualitative data obtained from patient focus groups and interviews, which informed the development of an initial list of items that described ICM side effects (SEs) and their impacts upon HRQOL. Physician surveys and interviews informed subsequent item generation/reduction. Cognitive debriefing interviews were conducted with a new set of patients after they completed the toxicity subscale.

Results

Focus groups and individual interviews with 37 ICM-treated patients generated an initial list of 176 items. Following a first round of item reduction that produced a shortened list of 76 items, 16 physicians who care for ICM treated patients were surveyed with a list of 49 patient reported toxicity related unique SEs; and 11 physicians participated in follow up interviews. Informed by the data collected from the physicians, a second round of item reduction produced a list of 25 items that covered a wide range of SEs including but not limited to gastrointestinal, cutaneous, musculoskeletal, respiratory, constitutional, neurological and endocrine. This final list was piloted with 11 patients who confirmed that it was comprehensible and complete.

Conclusions

This 25 item list is the first HRQOL toxicity subscale developed with patient and clinician input for patients treated with ICMs. The subscale will be combined with the FACT-G to form the FACT-ICM and this PRO instrument will undergo further validity testing.

Clinical trial identification

NCT02651831.

Editorial acknowledgement

Legal entity responsible for the study

Princess Margaret Cancer Centre.

Funding

University of Toronto, Strategic Innovation Grant.

Disclosure

A.R. Hansen: Advisory / Consultancy, Research grant / Funding (institution): Merck; Advisory / Consultancy, Research grant / Funding (institution): GSK; Advisory / Consultancy, Research grant / Funding (institution): Roche-Genentech; Advisory / Consultancy, Research grant / Funding (institution): MedImmune; Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca; Advisory / Consultancy, Research grant / Funding (institution): Boehringer Ingelheim; Research grant / Funding (institution): Boston Biomedical; Advisory / Consultancy, Research grant / Funding (institution): Novartis; Advisory / Consultancy, Research grant / Funding (institution): Bristol-Myers Squibb. P. Bedard: Research grant / Funding (institution): Bristol-Myers Squibb; Research grant / Funding (institution): Sanofi; Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): Genentech/Roche; Research grant / Funding (institution): Servier; Research grant / Funding (institution): GlaxoSmithKline; Research grant / Funding (institution): Novartis; Research grant / Funding (institution): SignalChem; Research grant / Funding (institution): PTC Therapeutics; Research grant / Funding (institution): Nektar; Research grant / Funding (institution): Merck; Research grant / Funding (institution): Seattle Genetics; Research grant / Funding (institution): Mersana; Research grant / Funding (institution): Immunomedics; Research grant / Funding (institution): Lilly. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.